Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

GSK to partner with Flagship Pioneering

by Rowan Walrath
August 5, 2024 | A version of this story appeared in Volume 102, Issue 24

 

GSK is partnering with venture firm Flagship Pioneering in a multipronged effort to develop up to 10 new medicines and vaccines. The two firms are providing $150 million collectively up front. GSK agreed to pay Flagship and any portfolio companies that enter the arrangement up to $720 million in additional development and milestone payments. The collaboration stems from Flagship’s Pioneering Medicines initiative, which has spearheaded partnerships with Novo Nordisk, Pfizer, and the Cystic Fibrosis Foundation.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.